Opportunity Information: Apply for RFA AI 14 049
Apply for RFA AI 14 049
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "NIAID SBIR Technology Transfer Direct Phase II (SBIR TT) (R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jul 2, 2014 and posted on Jul 2, 2014.
- Applicants must submit their applications by Nov 14, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria 1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor 2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture 3. (i) SBIR and STTR. Be a concern which is more than 50 percent directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50 percent directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these OR (ii) SBIR only. Be a concern which is more than 50 percent owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50 percent of the concern OR (iii) SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with 121.705(b) concerning registration and proposal requirements. 4. Has, including its affiliates, not more than 500 employees.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIAID SBIR Technology Transfer Direct Phase II (SBIR TT) funding opportunity (R44), published by the National Institutes of Health under Funding Opportunity Number RFA-AI-14-049, is designed to accelerate the movement of commercially viable diagnostic inventions created inside NIH intramural laboratories into the private marketplace. In practical terms, this announcement targets diagnostics that originated in research labs within NIAID (National Institute of Allergy and Infectious Diseases) and NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), and it invites eligible US small businesses to take those inventions further by doing the remaining research and development work needed to turn them into real products. The focus is explicitly on later-stage development and commercialization rather than early feasibility experiments, with the intent of shortening the time it takes for promising government-developed diagnostics to reach patients, clinicians, and public health users.
A central feature of the program is that it uses a "Direct to Phase II" SBIR mechanism. That structure is meant for projects that are already beyond the earliest proof-of-concept stage and are ready for advanced development without first completing a traditional SBIR Phase I under this specific award. In other words, NIH is signaling that applicants should be prepared to propose a Phase II-level plan with clear technical milestones and a credible commercialization path, since the objective is to speed R and D progress and help small businesses move faster toward market entry. The FOA frames this as a way to expand SBIR R and D opportunities for small business concerns while also increasing the pace of technology development and commercialization for diagnostics coming out of NIH intramural programs.
The opportunity is categorized as a discretionary grant, and it sits within health-related funding activity categories. The listed CFDA numbers reflect the scientific domains tied to the underlying NIH institutes and program areas, including 93.855 (Allergy and Infectious Diseases Research), 93.856 (Microbiology and Infectious Diseases Research), and 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research). While the announcement emphasizes diagnostics, the inclusion of these CFDA areas indicates that proposed development efforts may relate to infectious disease and immunology topics as well as diabetes, digestive, and kidney disease areas, so long as the work aligns with the specific intramural inventions intended for technology transfer and commercialization.
From a funding standpoint, the FOA lists an estimated total program funding level of $3,000,000 and an award ceiling of $1,000,000 per award, with no cost sharing or matching requirement. That means applicants are not required to provide matching funds as a condition of receiving the grant, which can matter for smaller companies that want to de-risk development before raising additional private capital. The ceiling also gives a sense of scale: these awards are meant to support substantive Phase II development work, but applicants should plan within the stated maximum and craft a development plan that fits both the technical needs of the diagnostic and the budget constraints typical of SBIR Phase II projects.
Eligibility is limited to United States small business concerns, and the announcement includes the standard SBIR definition and ownership requirements. To qualify, the business must be organized for profit, have a place of business in the United States, and primarily operate in the United States or otherwise make a significant contribution to the US economy through taxes or the use of American products, materials, or labor. The entity must fit an allowed legal form such as a sole proprietorship, partnership, LLC, corporation, joint venture, association, trust, or cooperative, with additional restrictions if the applicant is a joint venture, including limits on foreign participation. The small business must have no more than 500 employees including affiliates. Ownership rules follow SBIR standards, allowing either majority ownership by US citizens or permanent resident aliens (directly or through qualifying entities), or, for SBIR only, majority ownership by multiple venture capital operating companies, hedge funds, or private equity firms so long as no single such firm owns more than 50 percent. Joint ventures must ensure each participating entity meets the relevant ownership requirements, and certain registration and proposal requirements apply where venture capital-majority ownership is involved.
Key administrative details in the posted record show that the FOA was posted and created on July 2, 2014, with an original and current closing date of November 14, 2014, and an archive date of December 15, 2014. The listing provides an NIH grants.gov guide link for full details and directs applicants having technical trouble accessing the announcement to contact the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV. While the summary record highlights core program goals, eligibility, and funding limits, the full announcement linked in the guide would typically contain the specific list of eligible intramural inventions, expectations for technology transfer arrangements or licensing status, application content requirements, review criteria, and any special submission instructions associated with this Direct to Phase II SBIR Technology Transfer initiative.
Frequently Asked Questions (FAQs): NIAID SBIR Technology Transfer Direct Phase II (R44) - RFA-AI-14-049
What is this funding opportunity?
This is the NIAID SBIR Technology Transfer Direct Phase II (SBIR TT) funding opportunity using the R44 mechanism, published by the National Institutes of Health (NIH) under Funding Opportunity Number (FON) RFA-AI-14-049. It is intended to accelerate the transition of commercially viable diagnostic inventions created inside NIH intramural laboratories into the private marketplace.
What is the main purpose of the program?
The program is designed to shorten the time it takes for promising government-developed diagnostics to reach patients, clinicians, and public health users by supporting later-stage development and commercialization work in eligible U.S. small businesses.
What types of technologies does the FOA focus on?
The focus is explicitly on diagnostics that originated in NIH intramural research laboratories, specifically within NIAID (National Institute of Allergy and Infectious Diseases) and NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases). The emphasis is on taking those diagnostics through remaining research and development (R&D) steps needed to become real products.
What does "Technology Transfer" mean in this context?
In this context, technology transfer refers to moving diagnostic inventions created within NIH intramural labs into the private sector so a small business can perform the needed development work and pursue commercialization. The summary indicates the full announcement would typically include details on technology transfer arrangements or licensing status.
What is "Direct to Phase II" and how is it different from a traditional SBIR path?
"Direct to Phase II" means the opportunity is structured for projects that are already beyond early proof-of-concept and are ready for advanced development without first completing a traditional SBIR Phase I under this specific award. Applicants are expected to propose a Phase II-level R&D plan with clear technical milestones and a credible commercialization path.
Is this opportunity meant for early feasibility studies?
No. The opportunity emphasizes later-stage development and commercialization rather than early feasibility experiments. It is intended for diagnostics that are sufficiently mature to justify a Phase II-level development plan.
Which NIH institutes are highlighted for the intramural inventions targeted by this FOA?
The announcement targets diagnostics originating in intramural labs within NIAID and NIDDK.
What scientific or program areas are associated with this opportunity?
The listing includes CFDA numbers tied to relevant scientific domains: 93.855 (Allergy and Infectious Diseases Research), 93.856 (Microbiology and Infectious Diseases Research), and 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research). While the announcement emphasizes diagnostics, these areas indicate that projects may relate to infectious disease and immunology topics as well as diabetes, digestive, and kidney disease areas, as long as they align with the intramural inventions intended for technology transfer and commercialization.
What is the total estimated funding available under this FOA?
The FOA lists an estimated total program funding level of $3,000,000.
What is the maximum award amount per award?
The award ceiling is listed as $1,000,000 per award.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is limited to United States small business concerns that meet standard SBIR requirements.
What are the basic SBIR small business eligibility requirements mentioned?
Based on the summary provided, the business must be organized for profit, have a place of business in the United States, and primarily operate in the United States or otherwise make a significant contribution to the U.S. economy through taxes or the use of American products, materials, or labor. The business must also have no more than 500 employees, including affiliates.
What legal entity types are allowed to apply?
The opportunity references allowed legal forms including a sole proprietorship, partnership, LLC, corporation, joint venture, association, trust, or cooperative, subject to SBIR rules and additional restrictions that may apply (for example, for joint ventures and foreign participation limits).
Are joint ventures allowed?
Yes, joint ventures are listed among the allowed legal forms, but the summary notes additional restrictions apply, including limits on foreign participation, and that each participating entity must meet relevant ownership requirements.
What are the ownership requirements for eligibility?
The summary describes SBIR ownership rules allowing either (1) majority ownership by U.S. citizens or permanent resident aliens (directly or through qualifying entities), or (2) for SBIR only, majority ownership by multiple venture capital operating companies, hedge funds, or private equity firms, provided that no single such firm owns more than 50 percent. The summary also indicates that special registration and proposal requirements apply where venture capital-majority ownership is involved.
Is foreign participation allowed?
The summary indicates there are limits on foreign participation, particularly for joint ventures. Specific details would typically be in the full announcement.
What is the employee size limit for the applicant?
The small business must have no more than 500 employees, including affiliates.
What kind of work is the grant intended to support?
It is intended to support the remaining R&D needed to turn NIH intramural diagnostic inventions into real products, focusing on advanced development with technical milestones and a commercialization path.
What does NIH expect from applicants in terms of project readiness?
NIH is signaling that applicants should be prepared to submit a Phase II-level plan, meaning the project should be beyond early proof-of-concept and ready for advanced development, with clear technical milestones and a credible path to commercialization.
What type of grant is this categorized as?
The opportunity is categorized as a discretionary grant within health-related funding activity categories.
What is the Funding Opportunity Number (FON) and mechanism?
The Funding Opportunity Number is RFA-AI-14-049, and the mechanism is R44 (SBIR Technology Transfer Direct Phase II).
When was the FOA posted and when did it close?
The record shows the FOA was posted and created on July 2, 2014. The original and current closing date is listed as November 14, 2014. The archive date is December 15, 2014.
Where are full details expected to be found?
The listing references an NIH grants.gov guide link for full details. The summary notes that the full announcement would typically include the specific list of eligible intramural inventions, expectations for technology transfer arrangements or licensing status, application content requirements, review criteria, and any special submission instructions associated with the Direct to Phase II SBIR Technology Transfer initiative.
Who should be contacted for technical trouble accessing the announcement?
Applicants having technical trouble accessing the announcement are directed to contact the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: CCS BLM AZ Yuma Field Office (YFO) Internships
Previous opportunity: Notice of Intent to Award Rehabilitation of the Appalachian National Scenic Trail in Connecticut and Massachusetts
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 14 049
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 14 049) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIDDK Cooperative Hematology Specialized Core Centers (U54) Apply for RFA DK 14 001 Funding Number: RFA DK 14 001 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,000,000 |
| Limited Competition for the Continuation of the Adult Acute Liver Failure Study Group (U01) Apply for RFA DK 14 504 Funding Number: RFA DK 14 504 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $3,500,000 |
| NIDDK Physician Scientist Diversity Mentoring Award (K05) Apply for RFA DK 14 005 Funding Number: RFA DK 14 005 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| NIDDK Central Repositories Non renewable Sample Access (X01) Apply for PAR 14 301 Funding Number: PAR 14 301 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Type 1 Diabetes TrialNet Clinical Centers (U01) Apply for RFA DK 14 016 Funding Number: RFA DK 14 016 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $450,000 |
| Prevention of Lower Urinary Tract Symptoms in Women Bladder Health Scientific and Data Coordinating Center (PLUS SDCC) (U01) Apply for RFA DK 14 018 Funding Number: RFA DK 14 018 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Prevention of Lower Urinary Tract Symptoms in Women Bladder Health Clinical Centers (PLUS CCs) (U01) Apply for RFA DK 14 004 Funding Number: RFA DK 14 004 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| Limited Competition Data Coordinating Center for Type 1 Diabetes TrialNet (UC4) Apply for RFA DK 14 507 Funding Number: RFA DK 14 507 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $45,000,000 |
| Identification of Novel Targets and Pathways Mediating Weight Loss, Diabetes Resolution and Related Metabolic Disease after Bariatric Surgery in Humans (R01) Apply for RFA DK 14 025 Funding Number: RFA DK 14 025 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| Limited Competition for the Continuation of the Hepatitis B Research Network Clinical Centers (U01) Apply for RFA DK 14 506 Funding Number: RFA DK 14 506 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Hepatitis B Research Network Immunology Center (U01) Apply for RFA DK 14 509 Funding Number: RFA DK 14 509 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Hepatitis B Research Network Data Coordination Center (U01) Apply for RFA DK 14 510 Funding Number: RFA DK 14 510 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Type 1 Diabetes Complications IMPACT Award (DP3) Apply for RFA DK 14 017 Funding Number: RFA DK 14 017 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $2,000,000 |
| Consortium on Beta cell Death and Survival (HIRN CBDS) (UC4) Apply for RFA DK 14 021 Funding Number: RFA DK 14 021 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $900,000 |
| (Re)Building a Kidney Coordinating Center (U01) Apply for RFA DK 14 009 Funding Number: RFA DK 14 009 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,600,000 |
| (Re)Building a Kidney Cells to Organ (UH2/UH3) Apply for RFA DK 14 010 Funding Number: RFA DK 14 010 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Psychosocial and Behavioral Aspects of Bariatric Surgery (R01) Apply for RFA DK 14 026 Funding Number: RFA DK 14 026 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| Limited Competition for the Continuation of the SEARCH for Diabetes in Youth Cohort Study (UC4) Apply for RFA DK 14 508 Funding Number: RFA DK 14 508 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Innovative Research in HIV in Kidney, Urology and Hematology (R01) Apply for RFA DK 14 020 Funding Number: RFA DK 14 020 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| Elucidating HIV and HIV treatment Associated Metabolic/Endocrine Dysfunction (R01) Apply for RFA DK 14 023 Funding Number: RFA DK 14 023 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 14 049", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.